Synopsis
Synopsis
0
KDMF
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Amethopterin
2. Dicesium Salt Methotrexate
3. Hydrate, Methotrexate
4. Methotrexate Hydrate
5. Methotrexate Sodium
6. Methotrexate, (d)-isomer
7. Methotrexate, (dl)-isomer
8. Methotrexate, Dicesium Salt
9. Methotrexate, Disodium Salt
10. Methotrexate, Sodium Salt
11. Mexate
12. Sodium, Methotrexate
1. 59-05-2
2. Amethopterin
3. Rheumatrex
4. Methylaminopterin
5. Abitrexate
6. Trexall
7. Mexate
8. Metatrexan
9. Hdmtx
10. Methylaminopterinum
11. Mtx
12. (s)-2-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic Acid
13. Methotrexatum
14. Rasuvo
15. 4-amino-10-methylfolic Acid
16. Metotrexato
17. Maxtrex
18. Nsc-740
19. Mexate-aq
20. N-bismethylpteroylglutamic Acid
21. Folex
22. Nci-c04671
23. Cl-14377
24. Antifolan
25. Methotrexate Lpf
26. Xatmep
27. 133073-73-1
28. Amethopterine
29. Farmitrexat
30. Emt 25,299
31. L-amethopterin
32. Cl 14377
33. Methotrexat-ebewe
34. Tcmdc-125858
35. (2s)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic Acid
36. Abitrexate (methotrexate)
37. R 9985
38. Yl5fz2y5u1
39. Methotextrate
40. Methotrexat
41. Chembl34259
42. Nsc740
43. Chebi:44185
44. Adx-2191
45. N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-l-glutamic Acid
46. N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-l-glutamic Acid
47. Cl14377
48. Ncgc00025060-04
49. Nsc 740
50. 4-amino-n(10)-methylpteroylglutamic Acid
51. A-methopterin
52. Dsstox_cid_822
53. A-methpterin
54. Amethopterin L-
55. Folex-pfs
56. R-9985
57. (2s)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic Acid
58. Dsstox_rid_75810
59. Methotrexate, L-
60. Dsstox_gsid_20822
61. X 133
62. Metotressato [dcit]
63. Methotrexate, D-
64. Fauldexato
65. Medsatrexate
66. Methoblastin
67. Metotressato
68. Brimexate
69. Emthexat
70. Emthexate
71. Lantarel
72. Lumexon
73. Metrotex
74. Novatrex
75. Otrexup
76. Tremetex
77. Trexeron
78. Trixilem
79. Metex
80. Texate
81. Mls001401431
82. Methotrexatum [inn-latin]
83. Metotrexato [inn-spanish]
84. [3h]methotrexate
85. Smr000112001
86. [3h]-methotrexate
87. Folic Acid Antagonist
88. Ccris 1109
89. 4-aminomethylpteroylglutamic Acid
90. Hsdb 3123
91. L-(+)-n-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)glutamic Acid
92. N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-l-(+)-glutamic Acid
93. Sr-01000075682
94. Smr000449324
95. Einecs 200-413-8
96. Unii-yl5fz2y5u1
97. Metolate
98. Nordimet
99. Ai3-25299
100. Intradose-mtx
101. 4-amino-n(sup 10)-methylpteroylglutamic Acid
102. 1dhi
103. 1dhj
104. 2drc
105. 4ocx
106. (2s)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic Acid
107. Cas-59-05-2
108. Glutamic Acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, L-
109. Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-l-glutamova
110. Mpi-2505
111. Prestwick_322
112. Otrexup (tn)
113. Xatmep (tn)
114. Reditrex
115. Kyselina 4-amino-n(sup 10)-methylpteroylglutamova [czech]
116. Methylaminopterin; Mtx
117. Methotrexate [usan:usp:inn:ban:jan]
118. Spectrum_001836
119. Tocris-1230
120. 4kn0
121. Wr-19039
122. Prestwick0_000135
123. Prestwick1_000135
124. Prestwick2_000135
125. Spectrum2_001077
126. Spectrum3_000497
127. Spectrum4_000616
128. Spectrum5_000958
129. Methotrexate - Abitrexate
130. Methotrexate [mi]
131. N-(p-(((2,4-diamino-6-pteridyl)methyl)methylamino)benzoyl)glutamic Acid
132. Methotrexate [inn]
133. Methotrexate [jan]
134. L(+)-amethopterin Hydrate
135. Methotrexate [hsdb]
136. Methotrexate [iarc]
137. Methotrexate [inci]
138. Methotrexate [usan]
139. N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-l-glutamicacid
140. Ncimech_000767
141. Schembl3711
142. Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-l-glutamova [czech]
143. Methotrexate [vandf]
144. Bidd:pxr0175
145. Lopac0_000020
146. Kbiogr_001172
147. Kbioss_002341
148. Methotrexate [mart.]
149. Kyselina 4-amino-n(sup 10)-methylpteroylglutamova
150. Mls000049968
151. Mls002154208
152. Divk1c_000114
153. Methotrexate [usp-rs]
154. Methotrexate [who-dd]
155. Methotrexate [who-ip]
156. Spbio_001094
157. Spbio_002149
158. Amy235
159. Cid_126941
160. Cid_165528
161. Gtpl4674
162. Gtpl4815
163. Dtxsid4020822
164. Schembl12421860
165. Schembl23111732
166. Bdbm18050
167. Bdbm66082
168. Hms500f16
169. Kbio1_000114
170. Kbio2_002338
171. Kbio2_004906
172. Kbio2_007474
173. Kbio3_001493
174. Methotrexate (jp17/usp/inn)
175. G301
176. Ninds_000114
177. Bio1_000486
178. Bio1_000975
179. Bio1_001464
180. Hms1568k12
181. Hms2095k12
182. Hms2233o18
183. Hms3260c21
184. Hms3414l09
185. Hms3678l07
186. Hms3712k12
187. Methotrexate [orange Book]
188. Methotrexate [ep Monograph]
189. Methotrexate [usp Impurity]
190. Act03341
191. Apc-2002
192. Bcp13701
193. Mpi-5004
194. Zinc1529323
195. Methotrexate [usp Monograph]
196. Tox21_110944
197. Tox21_300269
198. Tox21_500020
199. Ccg-35800
200. Emt-25299
201. Methotrexatum [who-ip Latin]
202. Mfcd00064370
203. S1210
204. Stl535338
205. (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-l-glutamic Acid
206. Akos016340329
207. Tox21_110944_1
208. Cs-1732
209. Db00563
210. Ks-5093
211. Lp00020
212. Sdccgsbi-0050009.p003
213. Wr19039
214. Idi1_000114
215. N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-l-glutamic Acid
216. Smp2_000020
217. (methyl)amino)benzamido)pentanedioic Acid
218. Ncgc00025060-01
219. Ncgc00025060-02
220. Ncgc00025060-03
221. Ncgc00025060-05
222. Ncgc00025060-06
223. Ncgc00025060-07
224. Ncgc00025060-08
225. Ncgc00025060-09
226. Ncgc00025060-10
227. Ncgc00025060-11
228. Ncgc00025060-12
229. Ncgc00025060-13
230. Ncgc00025060-15
231. Ncgc00025060-16
232. Ncgc00254216-01
233. Ncgc00260705-01
234. Hy-14519
235. Eu-0100020
236. G-301
237. Sw198601-3
238. Methotrexate 1.0 Mg/ml In Dimethyl Sulfoxide
239. 73m731
240. A10021
241. C01937
242. D00142
243. Q422232
244. Sr-01000597411
245. W-60383
246. (s)-2-(4-(((2,4-diaminopteridin-6-yl)methyl)
247. Q-201366
248. Sr-01000075682-1
249. Sr-01000075682-2
250. Sr-01000075682-6
251. Sr-01000597411-1
252. W-105347
253. Brd-k59456551-001-09-3
254. Brd-k59456551-001-11-9
255. Wln: T66 Bn Dn Gn Jnj Cz Ez H1n1&r Dvmyvq2vq
256. Z1541638527
257. N,n,n,n-ethylenediaminetetra(methylenephosphonicacid)
258. Methotrexate, European Pharmacopoeia (ep) Reference Standard
259. Methotrexate, United States Pharmacopeia (usp) Reference Standard
260. Glutamic Acid,4-diamino-6-pteridinyl)methyl] Methylamino]benzoyl]-, L-(+)-
261. L-glutamic Acid,4-diamino-6-pteridinyl)methyl]- Methylamino]benzoyl]-
262. (s)-2-(4-(((2,4-diaminopteridin-6-yl)methyl)-(methyl)amino)benzamido)pentanedioic Acid
263. L-glutamic Acid,n-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-,hydrate(9ci)
264. Methotrexate For Peak Identification, European Pharmacopoeia (ep) Reference Standard
265. Methotrexate For System Suitability, European Pharmacopoeia (ep) Reference Standard
266. Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material
267. N-[4-[[(2,4-diamino-6-pteridinyl)methyl] Methylamino]benzoyl]-l-glutamic Acid
268. (2s)-2-((4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)amino)pentanedioic Acid
269. (2s)-2-[[[4-[(2,4-diamino-6-pteridinyl)methyl-methylamino]phenyl]-oxomethyl]amino]pentanedioic Acid;hydrate
270. (2s)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]glutaric Acid;hydrate
271. (2s)-2-[[4-[[2,4-bis(azanyl)pteridin-6-yl]methyl-methyl-amino]phenyl]carbonylamino]pentanedioic Acid;hydrate
272. 102613-64-9
273. L-glutamic Acid,n-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-, Hydrate (9ci)
274. Methotrexate, Pharmagrade, Manufactured Under Appropriate Controls For Use As A Raw Material In Pharma Or Biopharmaceutical Production, Meets Ep, Usp Testing Specifications
Molecular Weight | 454.4 g/mol |
---|---|
Molecular Formula | C20H22N8O5 |
XLogP3 | -1.8 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 9 |
Exact Mass | 454.17131583 g/mol |
Monoisotopic Mass | 454.17131583 g/mol |
Topological Polar Surface Area | 211 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 704 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Methotrexate sodium |
Drug Label | Methotrexate (formerly Amethopterin) is an antimetabolite used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. Chemically methotrexate is N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-... |
Active Ingredient | Methotrexate sodium |
Dosage Form | Tablet; Injectable |
Route | Injection; Oral |
Strength | eq 200mg base/8ml (eq 25mg base/ml); eq 250mg base/10ml (eq 25mg base/ml); eq 50mg base/2ml (eq 25mg base/ml); eq 2.5mg base; eq 100mg base/4ml (eq 25mg base/ml) |
Market Status | Prescription |
Company | Hospira; Roxane; Dava Pharms; Fresenius Kabi Usa; Eurohlth Intl; Mylan; Barr |
2 of 4 | |
---|---|
Drug Name | Trexall |
PubMed Health | Methotrexate |
Drug Classes | Antineoplastic Agent, Antipsoriatic, Antirheumatic, Antirheumatic, Cytotoxic |
Drug Label | Trexall (methotrexate tablets USP) (formerly Amethopterin) is an antimetabolite used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. Chemically methotrexate, USP is N-[4[[(2,4-diamino-6-pteridiny... |
Active Ingredient | Methotrexate sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 5mg base; eq 7.5mg base; eq 15mg base; eq 10mg base |
Market Status | Prescription |
Company | Barr |
3 of 4 | |
---|---|
Drug Name | Methotrexate sodium |
Drug Label | Methotrexate (formerly Amethopterin) is an antimetabolite used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. Chemically methotrexate is N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-... |
Active Ingredient | Methotrexate sodium |
Dosage Form | Tablet; Injectable |
Route | Injection; Oral |
Strength | eq 200mg base/8ml (eq 25mg base/ml); eq 250mg base/10ml (eq 25mg base/ml); eq 50mg base/2ml (eq 25mg base/ml); eq 2.5mg base; eq 100mg base/4ml (eq 25mg base/ml) |
Market Status | Prescription |
Company | Hospira; Roxane; Dava Pharms; Fresenius Kabi Usa; Eurohlth Intl; Mylan; Barr |
4 of 4 | |
---|---|
Drug Name | Trexall |
PubMed Health | Methotrexate |
Drug Classes | Antineoplastic Agent, Antipsoriatic, Antirheumatic, Antirheumatic, Cytotoxic |
Drug Label | Trexall (methotrexate tablets USP) (formerly Amethopterin) is an antimetabolite used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. Chemically methotrexate, USP is N-[4[[(2,4-diamino-6-pteridiny... |
Active Ingredient | Methotrexate sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 5mg base; eq 7.5mg base; eq 15mg base; eq 10mg base |
Market Status | Prescription |
Company | Barr |
Abortifacient Agents, Nonsteroidal; Antimetabolites, Antineoplastic; Antirheumatic Agents; Dermatologic Agents; Enzyme Inhibitors; Folic Acid Antagonists; Immunosuppressive Agents; Nucleic Acid Synthesis Inhibitors
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Methotrexate is indicated for treatment of breast carcinoma, head and neck cancers (epidermoid), non-small cell lung carcinoma (especially squamous cell types), small cell lung carcinoma, and gestational trophoblastic tumors (gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole). /Included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1911
Methotrexate is indicated for treatment of cervical carcinoma, ovarian carcinoma, bladder carcinoma, colorectal carcinoma, esophageal carcinoma, gastric carcinoma, pancreatic carcinoma, and penile carcinoma. /NOT included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1911
Methotrexate is indicated for treatment of acute lymphocytic leukemia and prophylaxis and treatment of meningeal leukemia. /Included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1911
For more Therapeutic Uses (Complete) data for METHOTREXATE (17 total), please visit the HSDB record page.
Methotrexate is a highly toxic drug with a very low therapeutic index and a therapeutic response is not likely to occur without some evidence of toxicity. ... When methotrexate is used in combination with other antineoplastic agents and/or radiation therapy, toxic reactions may be more severe than would occur with methotrexate therapy alone. Although doses of methotrexate used in the management of psoriasis and rheumatoid arthritis are usually lower than those used in antineoplastic chemotherapy, severe toxicity may occur in any patient receiving the drug and deaths have been reported with the use of methotrexate in the management of psoriasis and rheumatoid arthritis.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 1111
Methotrexate should be used with extreme caution in patients with infection, peptic ulcer, ulcerative colitis, or debility, and in very young or geriatric patients. Methotrexate should be used with extreme caution, if at all, in patients with malignant disease who have preexisting liver damage or impaired hepatic function, preexisting bone marrow depression, aplasia, leukopenia, thrombocytopenia, or anemia; the drug is usually contraindicated in patients with impaired renal function. In the management of psoriasis, methotrexate is contraindicated in patients with poor nutritional status or severe renal or hepatic disorders, those with overt or laboratory evidence of an immunodeficiency syndrome, and in those with preexisting blood dyscrasias such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or clinically important anemia; relative contraindications also include cirrhosis, active or recent hepatitis, or excessive alcohol consumption. In the management of rheumatoid arthritis, methotrexate is contraindicated in patients with preexisting blood dyscrasias such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or clinically important anemia; those with overt or laboratory evidence of immunodeficiency syndromes; and those with excessive alcohol consumption, alcoholic liver disease, or chronic liver disease.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 1112
Elevations in serum uric acid concentrations may occur in patients receiving methotrexate as a result of cell destruction and hepatic and renal damage. In some patients, uric acid nephropathy and acute renal failure may result. Tumor lysis syndrome associated with other cytotoxic drugs (e.g., fludarabine, cladribine), also has been reported in patients with rapidly growing tumors who were receiving methotrexate. Pharmacologic and appropriate supportive treatment may prevent or alleviate this complication. Methotrexate also was reported to precipitate acute gouty arthritis in two patients being treated for psoriasis. Administration of large volumes of fluids, alkalinization of the urine, and/or administration of allopurinol may be useful in preventing acute attacks of hyperuricemia and uric acid nephropathy.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 1111
Severe nephropathy manifested by azotemia, hematuria, and renal failure may occur in patients receiving methotrexate; fatalities have been reported. In one study, postmortem examination revealed extensive necrosis of the epithelium of the convoluted tubules. In patients with renal impairment, methotrexate accumulation and increased toxicity or additional renal damage may occur.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 1111
For more Drug Warnings (Complete) data for METHOTREXATE (22 total), please visit the HSDB record page.
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis. Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma. It is also used in the maintenance of acute lymphocytic leukemia. Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.
FDA Label
Nordimet is indicated for the treatment of:
- active rheumatoid arthritis in adult patients,
- polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,
- severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, psoralens and ultraviolet A (PUVA), and retinoids, and severe psoriatic arthritis in adult patients,
- induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.
Methotrexate inhibits enzymes responsible for nucleotide synthesis which prevents cell division and leads to anti-inflammatory actions. It has a long duration of action and is generally given to patients once weekly. Methotrexate has a narrow therapeutic index. Do not take methotrexate daily.
Abortifacient Agents, Nonsteroidal
Non-steroidal chemical compounds with abortifacient activity. (See all compounds classified as Abortifacient Agents, Nonsteroidal.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Antimetabolites, Antineoplastic
Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
Antirheumatic Agents
Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
Folic Acid Antagonists
Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)
Nucleic Acid Synthesis Inhibitors
Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)
L04AX03
L04AX03
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01B - Antimetabolites
L01BA - Folic acid analogues
L01BA01 - Methotrexate
L - Antineoplastic and immunomodulating agents
L04 - Immunosuppressants
L04A - Immunosuppressants
L04AX - Other immunosuppressants
L04AX03 - Methotrexate
Absorption
Methotrexate has a bioavailability of 64-90%, though this decreases at oral doses above 25mg due to saturation of the carrier mediated transport of methotrexate.. Methotrexate has a Tmax of 1 to 2 hours. oral doses of 10-15g reach serum levels of 0.01-0.1M.
Route of Elimination
Methotrexate is >80% excreted as the unchanged drug and approximately 3% as the 7-hydroxylated metabolite. Methotrexate is primarily excreted in the urine with 8.7-26% of an intravenous dose appearing in the bile.
Volume of Distribution
The volume of distribution of methotrexate at steady state is approximately 1L/kg.
Clearance
Methotrexate clearance varies widely between patients and decreases with increasing doses. Currently, predicting clearance of methotrexate is difficult and exceedingly high serum levels of methotrexate can still occur when all precautions are taken.
In adults, oral absorption of methotrexate appears to be dose dependent. Peak serum levels are reached within one to two hours. At doses of 30 mg/sq m or less, methotrexate is generally well absorbed with a mean bioavailability of about 60%. The absorption of doses greater than 80 mg/sq m is significantly less, possibly due to a saturation effect.
Physicians Desk Reference. 58th ed. Thomson PDR. Montvale, NJ 2004., p. 806
After intravenous administration, the initial volume of distribution is approximately 0.18 L/kg (18% of body weight) and steady-state volume of distribution is approximately 0.4 to 0.8 L/kg (40% to 80% of body weight).
Physicians Desk Reference. 58th ed. Thomson PDR. Montvale, NJ 2004., p. 806
Protein binding: Moderate (approximately 50%), primarily to albumin.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1912
At serum methotrexate concentrations exceeding 0.1 umol/mL passive diffusion becomes a major means of intracellular transport of the drug. The drug is widely distributed into body tissues with highest concn in the kidneys, gallbladder, spleen, liver, and skin.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 1113
For more Absorption, Distribution and Excretion (Complete) data for METHOTREXATE (10 total), please visit the HSDB record page.
Methotrexate is metabolized by folylpolyglutamate synthase to methotrexate polyglutamate in the liver as well as in tissues. Gamma-glutamyl hydrolase hydrolyzes the glutamyl chains of methotrexate polyglutamates converting them back to methotrexate. A small amount of methotrexate is also converted to 7-hydroxymethotrexate.
After absorption, methotrexate undergoes hepatic and intracellular metabolism to form methotrexate polyglutamate, metabolites which by hydrolysis may be converted back to methotrexate. Methotrexate polyglutamates inhibit dihydrofolate reductase and thymidylate synthetase. Small amounts of these polyglutamate metabolites may remain in tissues for extended periods; the retention and prolonged action of these active metabolites vary among different cells, tissues, and tumors. In addition, small amounts of methotrexate polyglutamate may be converted to 7-hydroxymethotrexate; accumulation of this metabolite may become substantial following administration of high doses of methotrexate, since the aqueous solubility of 7-hydroxymethotrexate is threefold to fivefold lower than that of the parent compound. Following oral administration of methotrexate, the drug also is partially metabolized by the intestinal flora.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 1113
The half life of low dose methotrexate is 3 to 10 hours in adults. The half life for high dose methotrexate is 8 to 15 hours. Pediatric patients taking methotrexate for acute lymphoblastic anemia experience a terminal half life of 0.7 to 5.8 hours. Pediatric patients taking methotrexate for juvenile idiopathic arthritis experience a half life of 0.9 to 2.3 hours.
Terminal: Low doses: 3 to 10 hours. High doses: 8 to 15 hours. Note: There is wide interindividual variation in clearance rates. Small amounts of methotrexate and its metabolites are protein-bound and may remain in tissues (kidneys, liver) for weeks to months; the presence of fluid loads, such as ascites or pleural effusion, and renal function impairment will also delay clearance.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1912
Methotrexate enters tissues and is converted to a methotrexate polyglutamate by folylpolyglutamate. Methotrexate's mechanism of action is due to its inhibition of enzymes responsible for nucleotide synthesis including dihydrofolate reductase, thymidylate synthase, aminoimidazole caboxamide ribonucleotide transformylase (AICART), and amido phosphoribosyltransferase. Inhibtion of nucleotide synthesis prevents cell division. In rheumatoid arthritis, methotrexate polyglutamates inhibit AICART more than methotrexate. This inhibition leads to accumulation of AICART ribonucleotide, which inhibits adenosine deaminase, leading to an accumulation of adenosine triphosphate and adenosine in the extracellular space, stimulating adenosine receptors, leading to anti-inflammatory action.
Methotrexate and its polyglutanate metabolites reversibly inhibits dihydrofolate reductase, the enzyme that reduces folic acid to tetrahydrofolic acid. Inhibition of tetrahydrofolate formation limits the availability of one-carbon fragments necessary for synthesis of purines and the conversion of deoxyuridylate to thymidylate in the synthesis of DNA and cell reproduction. The affinity of dihydrofolate reductase for methotrexate is far greater than its affinity for folic acid or dihydrofolic acid. and, therefore, even very large doses of folic acid given simultaneously will not reverse the effects of methotrexate. Leucovorin calcium, a derivative of tetrahydrofolic acid, may block the effects of methotrexate if given shortly after the antineoplastic agent. Results of one study indicate that methotrexate also causes an increase in intracellular deoxyadenosine triphosphate, which is thought to inhibit ribonucleotide reduction, and polynucleotide ligase, an enzyme concerned in DNA synthesis and repair. Tissues with high rates of cellular proliferation such as neoplasms, psoriatic epidermis, bone marrow, the lining of the GI tract, hair matrix, and fetal cells are most sensitive to the effects of methotrexate.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 1113
Methotrexate ... has immunosuppressive activity, in part possibly as a result of inhibition of lymphocyte multiplication. The mechanism(s) of action in the management of rheumatoid arthritis of the drug is not known, although suggested mechanisms have included immunosuppressive and/or antiinflammatory effects.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 1113
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-04-28
Pay. Date : 2014-04-17
DMF Number : 23532
Submission : 2010-01-29
Status : Active
Type : II
NDC Package Code : 12780-0491
Start Marketing Date : 1981-11-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF, BR |
Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39988
Submission : 2024-06-05
Status : Active
Type : II
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-10-04
Pay. Date : 2013-09-26
DMF Number : 11704
Submission : 1995-10-05
Status : Active
Type : II
Certificate Number : R0-CEP 2022-373 - Rev 00
Issue Date : 2022-12-13
Type : Chemical
Substance Number : 560
Status : Valid
Registration Number : 219MF10360
Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY
Initial Date of Registration : 2007-12-13
Latest Date of Registration : --
NDC Package Code : 46014-1023
Start Marketing Date : 2013-05-06
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Available Reg Filing : ASMF, CN |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25957
Submission : 2012-04-10
Status : Active
Type : II
Certificate Number : R1-CEP 2008-238 - Rev 02
Issue Date : 2020-02-07
Type : Chemical
Substance Number : 560
Status : Valid
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39758
Submission : 2024-03-24
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-04-28
Pay. Date : 2014-04-17
DMF Number : 23532
Submission : 2010-01-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-06-08
Pay. Date : 2013-05-23
DMF Number : 4246
Submission : 1981-08-06
Status : Active
Type : II
Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39988
Submission : 2024-06-05
Status : Active
Type : II
Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.
GDUFA
DMF Review : Complete
Rev. Date : 2013-10-04
Pay. Date : 2013-09-26
DMF Number : 11704
Submission : 1995-10-05
Status : Active
Type : II
Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.
GDUFA
DMF Review : Complete
Rev. Date : 2018-11-26
Pay. Date : 2018-11-16
DMF Number : 12472
Submission : 1997-04-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25957
Submission : 2012-04-10
Status : Active
Type : II
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39758
Submission : 2024-03-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6122
Submission : 1985-12-12
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4018
Submission : 1980-11-11
Status : Inactive
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3124
Submission : 1978-02-03
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 12780-6690
Start Marketing Date : 2010-01-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 12780-0491
Start Marketing Date : 1981-11-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.
NDC Package Code : 46014-1023
Start Marketing Date : 2013-05-06
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.
NDC Package Code : 46014-1133
Start Marketing Date : 2017-11-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.
NDC Package Code : 46014-1119
Start Marketing Date : 2013-06-12
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 46708-939
Start Marketing Date : 2024-01-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63660-0006
Start Marketing Date : 2017-12-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51927-1565
Start Marketing Date : 2013-06-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 49452-4601
Start Marketing Date : 2000-12-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 58623-0040
Start Marketing Date : 2012-03-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & F...
Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.
About the Company : Transform your biologic formulations with Pfanstiehl, the industry leader in High-Purity Low Endotoxin Low Metals Parenteral grade excipient manufacturing. Our expertise spans isol...
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
About the Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialzation. With our...
Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.
About the Company : Fareva’s API division has special technologies for high potent APIs (HPAPIs) down to the OEB-6 level, aseptic crystallization (sterile APIs), Spray Drying etc, with volumes rangi...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : Established in 1996, CF Pharma Ltd. is a privately owned, independent developer & producer of APIs headquartered in Budapest, Hungary. It specializes in the development & manufactu...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
About the Company : Specializing in natural & oncology APIs, we establish R&D and production platforms for new salt, crystal form & synthetic biology research. We cooperate with clients for IND, NDA, ...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : Generic
Registration Country : Canada
Brand Name :
Dosage Form : TABLET
Dosage Strength : 2.5MG
Packaging :
Approval Date :
Application Number : 40233
Regulatory Info : Generic
Registration Country : Canada
Regulatory Info : Generic ANDA Granted, Available outside USA
Registration Country : Canada
Brand Name :
Dosage Form : TABLET
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic ANDA Granted, Available outside USA
Registration Country : Canada
Regulatory Info :
Registration Country : Sweden
Brand Name : Methotrexate Orion
Dosage Form : TABLETT
Dosage Strength : 2,5 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Methotrexate Orion
Dosage Form : INJEKTIONSVÄTSKA, LÖSNING, FÖRFYLLD SPRUTA
Dosage Strength : 25 MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Methotrexate Orion
Dosage Form : Injection fluid, resolution in the finished filled syringe
Dosage Strength : 25 mg/ml
Packaging : Finish filled syringe
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Methotrexate Orion
Dosage Form : Injection fluid, resolution in the finished filled syringe
Dosage Strength : 25 mg/ml
Packaging : Finish filled syringe
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Methotrexate Orion
Dosage Form : Injection fluid, resolution in the finished filled syringe
Dosage Strength : 25 mg/ml
Packaging : Finish filled syringe
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Methotrexate Orion
Dosage Form : Injection fluid, resolution in the finished filled syringe
Dosage Strength : 25 mg/ml
Packaging : Finish filled syringe
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Methotrexate Orion
Dosage Form : Injection fluid, resolution in the finished filled syringe
Dosage Strength : 25 mg/ml
Packaging : Finish filled syringe
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.
Regulatory Info : Dossier Availability: Q3 2026
Registration Country : Poland
Brand Name :
Dosage Form : Solution for Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : Dossier Availability: Q3 2026
Registration Country : Poland
RLD : Yes
TE Code :
Brand Name : METHOTREXATE SODIUM
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 1982-01-01
Application Number : 8085
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : No
TE Code :
Brand Name : ABITREXATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 250MG BASE/VIAL
Approval Date : 1987-07-17
Application Number : 89356
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : METHOTREXATE SODIUM
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2.5MG BASE
Approval Date : 2020-01-24
Application Number : 213343
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : METHOTREXATE SODIUM
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2.5MG BASE
Approval Date : 1990-10-15
Application Number : 81099
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : MEXATE-AQ PRESERVED
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 25MG BASE/ML
Approval Date : 1989-04-14
Application Number : 89887
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : METHOTREXATE SODIUM
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2.5MG BASE
Approval Date : 2023-08-07
Application Number : 213362
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code :
Brand Name : METHOTREXATE PRESERVATIVE FREE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)
Approval Date : 2005-04-13
Application Number : 11719
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : RASUVO
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : 20MG/0.4ML (20MG/0.4ML)
Approval Date : 2014-07-10
Application Number : 205776
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD :
TE Code :
Brand Name : METHOTREXATE SODIUM
Dosage Form : Injectable; Injection
Dosage Strength : EQ 25MG BASE/ML
Approval Date :
Application Number : 89309
RX/OTC/DISCN :
RLD :
TE Code :
RLD : No
TE Code : AB
Brand Name : METHOTREXATE SODIUM
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2.5MG BASE
Approval Date : 1992-05-15
Application Number : 81235
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.
Regulatory Info : Dossier Availability: Q3 2026
Registration Country : Poland
Brand Name :
Dosage Form : Solution for Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : Dossier Availability: Q3 2026
Registration Country : Poland
Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.
Packaging :
Regulatory Info : Dossier Availability: Q3 2026
Dosage : Solution for Injection
Dosage Strength : 50MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Poland
Regulatory Info :
Registration Country : Iran
Brand Name : Reximed
Dosage Form : Vial
Dosage Strength : 50MG/2ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 50MG/2ML
Brand Name : Reximed
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Reximed
Dosage Form : Vial
Dosage Strength : 1000MG/10ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 1000MG/10ML
Brand Name : Reximed
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Reximed
Dosage Form : Vial
Dosage Strength : 50MG/2ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 50MG/2ML
Brand Name : Reximed
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Reximed
Dosage Form : Vial
Dosage Strength : 1000MG/10ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 1000MG/10ML
Brand Name : Reximed
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Trexoma
Dosage Form : Prefilled Syringe
Dosage Strength : 7.5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Prefilled Syringe
Dosage Strength : 7.5MG
Brand Name : Trexoma
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Trexoma
Dosage Form : Prefilled Syringe
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Prefilled Syringe
Dosage Strength : 10MG
Brand Name : Trexoma
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Trexoma
Dosage Form : Prefilled Syringe
Dosage Strength : 15MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Prefilled Syringe
Dosage Strength : 15MG
Brand Name : Trexoma
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Trexoma
Dosage Form : Prefilled Syringe
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Prefilled Syringe
Dosage Strength : 20MG
Brand Name : Trexoma
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Trexoma
Dosage Form : Prefilled Syringe
Dosage Strength : 25MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Prefilled Syringe
Dosage Strength : 25MG
Brand Name : Trexoma
Approval Date :
Application Number :
Registration Country : Iran
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2029-06-01
US Patent Number : 8664231
Drug Substance Claim :
Drug Product Claim :
Application Number : 205776
Patent Use Code : U-1442
Delist Requested :
Patent Use Description : SUBCUTANEOUS INJECTION...
Patent Expiration Date : 2029-06-01
Patent Expiration Date : 2026-01-24
US Patent Number : 8562564
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 204824
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-01-24
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2029-03-10
US Patent Number : 11684723
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 204824
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-03-10
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2029-03-10
US Patent Number : 10709844
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 204824
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-03-10
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2029-03-10
US Patent Number : 11684723
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 204824
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-03-10
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2030-03-19
US Patent Number : 8579865
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 204824
Patent Use Code : U-1442
Delist Requested :
Patent Use Description : SUBCUTANEOUS INJECTION...
Patent Expiration Date : 2030-03-19
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2026-01-24
US Patent Number : 11446441
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 204824
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-01-24
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Exclusivity Code : ODE-137
Exclusivity Expiration Date : 2024-04-25
Application Number : 208400
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-138
Exclusivity Expiration Date : 2024-04-25
Application Number : 208400
Product Number : 1
Exclusivity Details :
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?